Literature DB >> 19551867

BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.

Moltira Promkan1, Guangming Liu, Pimpicha Patmasiriwat, Subhas Chakrabarty.   

Abstract

BRCA1 is a multifunctional tumor-suppressive protein. Many functional aspects of BRCA1 are not fully understood. We used a shRNA approach to probe the function of BRCA1 in human breast cancer cells. Knocking down BRCA1 expression by shRNA in the wild-type BRCA1 human breast cancer MCF-7 and MDA-MB-231 cells resulted in an increase in cell proliferation, anchorage-independent growth, cell migration, invasion and a loss of p21/Waf1 and p27Kip1 expression. In BRCA1 knocked-down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel. We also found that cells harboring endogenous mutant or defective BRCA1 (MDA-MB-436 and HCC1937) were highly proliferative and expressed a relatively low level of p21/Waf1 and p27Kip1 by comparison to wild-type BRCA1 cells. Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild-type cells. Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. We conclude that BRCA1 down-modulates the malignant behavior of breast cancer cells, promotes the expression of p21/Waf1, p27Kip1 and inhibits the expression of survivin. Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel. Copyright (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19551867     DOI: 10.1002/ijc.24684

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.

Authors:  Natalia Bednarz; Elke Eltze; Axel Semjonow; Michael Rink; Antje Andreas; Lennart Mulder; Juliane Hannemann; Margit Fisch; Klaus Pantel; Heinz-Ulrich G Weier; Krzysztof P Bielawski; Burkhard Brandt
Journal:  Clin Cancer Res       Date:  2010-06-30       Impact factor: 12.531

2.  The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.

Authors:  Danny Vesprini; Steven A Narod; John Trachtenberg; Juanita Crook; Farid Jalali; John Preiner; Srikala Sridhar; Robert G Bristow
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

3.  Prognostic significance of calcium-sensing receptor in breast cancer.

Authors:  Xiaoyan Li; Li Li; Meena S Moran; Liyu Jiang; Xiangnan Kong; Hongyu Zhang; Xin Zhang; Bruce G Haffty; Qifeng Yang
Journal:  Tumour Biol       Date:  2014-03-01

4.  BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.

Authors:  Da Li; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Xiu-Xia Wang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Delocalization of gamma-tubulin due to increased solubility in human breast cancer cell lines.

Authors:  Edward H Cho; Rebecca A Whipple; Michael A Matrone; Eric M Balzer; Stuart S Martin
Journal:  Cancer Biol Ther       Date:  2010-01-28       Impact factor: 4.742

6.  A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.

Authors:  Da Li; Fang-Fang Bi; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Qing Yang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Drug therapy for hereditary cancers.

Authors:  Evgeny N Imyanitov; Vladimir M Moiseyenko
Journal:  Hered Cancer Clin Pract       Date:  2011-08-06       Impact factor: 2.857

8.  Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage.

Authors:  A Reeder; M Attar; L Nazario; C Bathula; A Zhang; D Hochbaum; E Roy; K L Cooper; S Oesterreich; N E Davidson; C A Neumann; M S Flint
Journal:  Br J Cancer       Date:  2015-04-16       Impact factor: 7.640

9.  The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.

Authors:  Moltira Promkan; Sumana Dakeng; Subhas Chakrabarty; Oliver Bögler; Pimpicha Patmasiriwat
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

10.  Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma.

Authors:  Elyse L Walk; Scott A Weed
Journal:  Cancers (Basel)       Date:  2011-02-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.